Agoracom: Small Cap Investment - Mosaic ImmunoEngineering Inc. - Re:SGE 148 OR 336 will at least double the SP.

Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Reply New Message

Prev Message Back To Forum Threaded View Next Message

optymystic

Rank: President [?]

Points: 18922 [?]

Votes: 159 Score: 3.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re:SGE 148 OR 336 will at least double the SP. - emtnester

in response to

Re:SGE 148 OR 336 will at least double the SP.

emtnester

posted on Aug 02, 2008 02:57PM

I think you might be wrong about being a continuation patent. From the 148 patent:

This application is a divisional of U.S. patent application No. 08/484,918, filed Jun. 7, 1995, now U.S. Pat. No. 5,809,336 which is a divisional of U.S. patent application No. 07/389,334, filed Aug. 3, 1989 now U.S. Pat. No. 5,982,231.

Apparently someone got the patent number wrong. Application 07/389334 is for the 749 patent. Doesn't anyone look at this stuff?

And the definition of Divisional patent

A "divisional application" also claims filing date priority from the parent, but differs from a "continuation application" in that a divisional application claims a distinct or independent invention based upon pertinent parts "carved out" of the parent application's specification.